ProQR Therapeutics - PRQR Income before deduction of interest, taxes and amortization
ProQR Therapeutics N.V. (PRQR) is actively scaling RNA editing innovations to combat hereditary pathologies. The GURU.Markets terminal displays the company's absolute operating profit in cash terms, where 0.00 represents the current metric value. Growth is driven by alliances with pharma behemoths and patent licensing, as well as the Axiomer platform and the monetization of intellectual property.
Summary analytical data breakdowns for ProQR Therapeutics (PRQR)
- stock quotes and analyst forecast:
- issuer market value details:
- book capitalization information:
- company total debt and liquidity indicators:
Debt to Capital ProQR Therapeutics N.V.|PRQR - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ProQR|PRQR - Company Aggregate Debts|Debts to Book Capitalization ProQR Therapeutics N.V.|PRQR - Company Long-Term Debt|Current Liabilities ProQR Therapeutics N.V.|Immediate Liquidity proqr.com
- financial results and valuation multiples details:
PRQR - Net Income|Projected Future Earnings ProQR Therapeutics N.V.|PRQR - Price to Earnings Ratio|Market Cap to Future Earnings Ratio ProQR|PRQR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio ProQR Therapeutics N.V.|PRQR - Operating profit EBITDA|Net earnings per share for the last 12 months ProQR Therapeutics N.V.|PRQR - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months proqr.com|PRQR - Net earnings per share growth this year|Expected earnings per share trend next year ProQR Therapeutics N.V.
Summary company analytics:PRQR (ProQR Therapeutics N.V.)
This indicator captures the daily inflow of actual cash from core operations, allowing for an assessment of current liquidity and operational resilience without accounting for accruals. By analyzing EBITDA dynamics, an investor can see the actual cash flow, which is critically important for ProQR Therapeutics (PRQR) when funding the development of the Axiomer platform and preparing clinical data in partnership with pharma behemoths.
Competitors of ProQR Therapeutics N.V. (PRQR)
Income before deduction of interest, taxes and amortization TEM|QGEN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|RGEN (Repligen) - Operating profit before deduction of amortization|RNA: Company profit before taxes, interest and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|BEAM - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|NTLA - Operating profit EBITDA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization BLFS (biolifesolutions.com)|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Operating profit before deduction of amortization SION (Sionna Pharma)|Operating profit EBITDA Prime Medicine Bio (PRME)|Taysha Gene Therapies - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization QURE (uniqure.com)|MeiraGTx - Operating profit EBITDA|Operating income before deduction of amortization REGENXBIO Inc RGNX|SLDB: Operating profit EBITDA|Operating profit before deduction of amortization Ocugen Pharma|Profit before payment of interest, taxes and amortization Pacific Biosciences|benitec.com (BNTC) - Operating income before deduction of amortization|Operating profit before deduction of amortization DSGN (Design Therapeutics, Inc.)|RCKT (Rocket Pharma) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|LXEO: Operating profit before amortization|KRRO: Operating profit before deduction of amortization|Operating income before deduction of amortization editasmedicine.com EDIT|SLN (Silence Therapeutics plc) - Operating profit before deduction of amortization|CDXS (Codexis) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization SGMO|Nautilus Biotechnology Inc (NAUT) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|DTIL: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Generation Bio GBIO|Income before deduction of interest, taxes and amortization BOLD|XCUR - Profit before payment of interest, taxes and amortization|Operating profit before depreciation charges Imunon, Inc. (IMNN)|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Mustang Bio - Income before deduction of interest, taxes and amortization|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Operating profit before amortization BNGO (Bionano)|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|bluebird bio, Inc - Operating profit before amortization|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating profit EBITDA omegatherapeutics.com OMGA|OMIC - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization RGLS|Syros (SYRS) - Profit before payment of interest, taxes and amortization|Telesis Bio, Inc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Profit before interest, taxes and amortization unitybiotechnology.com UBX
